Bavarian Nordic released preliminary 2025 financial results on February 12, 2026.
Revenue expected to dip slightly in 2026 due to absence of mpox outbreak effects.
2025 full-year EBITDA margin reached 28%, exceeding guidance of 26%.
Travel Health revenue contributed to Q4 revenue beat.
Plans to launch chikungunya vaccine in Switzerland and Canada in H1 2026, expected to drive growth.
Full 2025 Annual Report scheduled for March 12, 2026.